Vojtičková Margaréta, Dobiaš Juraj, Hanquet Gilles, Addová Gabriela, Cetin-Atalay Rengul, Yildirim Deniz Cansen, Boháč Andrej
Université de Strasbourg, Ecole européenne de Chimie, Polymères et Matériaux (ECPM) Laboratoire de Synthèse et Catalyse (UMR CNRS 7509), 25, rue Becquerel, F-67087 Strasbourg, France; Comenius University in Bratislava, Faculty of Natural Sciences, Department of Organic Chemistry, Mlynská dolina, 842 15 Bratislava, Slovakia.
Comenius University in Bratislava, Faculty of Natural Sciences, Department of Organic Chemistry, Mlynská dolina, 842 15 Bratislava, Slovakia.
Eur J Med Chem. 2015 Oct 20;103:105-22. doi: 10.1016/j.ejmech.2015.08.012. Epub 2015 Aug 8.
Structure novelty, chemical stability and synthetic feasibility attracted us to design 1,2,3-triazole compounds as potential inhibitors of VEGFR2 tyrosine kinase. Novel triazoles T1-T7 were proposed by oxazole (AAZ from PDB: 1Y6A)/1,2,3-triazole isosteric replacement, molecular modelling and docking. In order to enable synthesis of T1-T7 we developed a methodology for preparation of ynamide 22. Compound 22 was used for all Click chemistry reactions leading to triazoles T1-T3 and T6-T7. Among the obtained products, T1, T3 and T7 specifically bind VEGFR2 TK and modulate its activity by concentration dependent manner. Moreover predicted binding poses of T1-T7 in VEGFR2 TK were similar to the one known for the oxazole inhibitor AAZ (PDB: 1Y6A). Unfortunately the VEGFR2 inhibition by triazoles e.g. T3 and T7 is lower than that determined for their oxazole bioisosters T3-ox and AAZ, resp. Different electronic properties of 1,2,3-triazole/oxazole heterocyclic rings were proposed to be the main reason for the diminished affinity of T1-T3, T6 and T7 to an oxazole AAZ inhibitor binding site in VEGFR2 TK (PDB: 1Y6A or 1Y6B). Moreover T1-T3 and T6 were screened on cytotoxic activity against two human hepatocellular carcinoma cell lines. Selective cytotoxic activity of T2 against aggressive Mahlavu cells has been discovered indicating possible affinity of T2 to Mahlavu constitutionally active PI3K/Akt pathway.
结构新颖性、化学稳定性和合成可行性吸引我们设计1,2,3-三唑化合物作为血管内皮生长因子受体2(VEGFR2)酪氨酸激酶的潜在抑制剂。通过恶唑(来自蛋白质数据库(PDB):1Y6A的AAZ)/1,2,3-三唑等电子体替换、分子建模和对接,提出了新型三唑T1-T7。为了能够合成T1-T7,我们开发了一种制备炔酰胺22的方法。化合物22用于所有导致三唑T1-T3和T6-T7的点击化学反应。在所获得的产物中,T1、T3和T7特异性结合VEGFR2酪氨酸激酶,并以浓度依赖性方式调节其活性。此外,T1-T7在VEGFR2酪氨酸激酶中的预测结合构象与恶唑抑制剂AAZ(PDB:1Y6A)已知的构象相似。不幸的是,三唑如T3和T7对VEGFR2的抑制作用低于其恶唑生物电子等排体T3-ox和AAZ分别测定的抑制作用。有人提出,1,2,3-三唑/恶唑杂环不同的电子性质是T1-T3、T6和T7与VEGFR2酪氨酸激酶(PDB:1Y6A或1Y6B)中恶唑AAZ抑制剂结合位点亲和力降低的主要原因。此外,还对T1-T3和T6针对两种人肝癌细胞系的细胞毒性活性进行了筛选。已发现T2对侵袭性Mahlavu细胞具有选择性细胞毒性活性,表明T2可能与Mahlavu组成型活性PI3K/Akt途径具有亲和力。